Acesso livre
Acesso livre

Medicina de Emergências

Nova diretriz do CDC encurta os períodos de isolamento e quarentena para a Covid-19; pacientes que testaram positivo devem se isolar por 5 dias e, se assintomáticos após esse período, podem deixar o isolamento caso continuem usando máscaras por 5 dias, para minimizar o risco de infectar outras pessoas.

10 Jan, 2022 | 12:51h

CDC Updates and Shortens Recommended Isolation and Quarantine Period for General Population – Centers for Disease Control and Prevention

Ver também: Quarantine and Isolation – Centers for Disease Control and Prevention

Comentários:

Facing criticism, CDC updates Covid-19 isolation recommendations with guidance on testing – CNN

CDC posts rationale for shorter isolation, quarantine – Associated Press

Covid-19: CDC shortens isolation period as US cases hit record high – The BMJ

Shortened CDC COVID isolation guide draws sharply mixed reviews – CIDRAP

New CDC isolation guidelines raise concerns among health experts – NPR

CDC Reduces Recommended Isolation Time for People With COVID-19 – HealthDay

COVID isolation and quarantine period for general population shortened by CDC – News Medical

CDC shortens recommended Covid-19 isolation and quarantine time – CNN

CDC cuts the recommended isolation and quarantine periods for coronavirus infections – NPR

US officials recommend shorter COVID isolation, quarantine – Associated Press

Ver novas recomendações de outros países:

France cuts isolation times and plans crackdown on unvaccinated amid record surge in Covid cases – CNN

Covid: Self-isolation cut from 10 days to seven with negative tests – BBC

[Preprint] Estudo randomizado | Em adultos sintomáticos com mais de 18 anos e com teste positivo para SARS-CoV-2, o tratamento ambulatorial precoce com plasma convalescente com altos títulos de anticorpos reduziu significativamente as internações.

10 Jan, 2022 | 12:39h

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma – medRxiv

Comunicado de imprensa: Early Use of Convalescent Plasma May Help Outpatients with COVID-19 Avoid Hospitalization – Johns Hopkins Medicine

Comentário: Convalescent plasma shows renewed promise for COVID-19 in outpatient trial – Science

Estudo randomizado | Molnupiravir reduziu o risco de internação ou morte por Covid-19 de pacientes adultos não vacinados sob risco (p.ex., com obesidade, idade acima de 60 anos etc.).

17 Dez, 2021 | 12:28h

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients – New England Journal of Medicine

Conteúdo relacionado: Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature (vários artigos sobre o tema)

Diretriz NICE | Insuficiência cardíaca aguda: diagnóstico e tratamento.

17 Dez, 2021 | 12:16h

Acute heart failure: diagnosis and management – National Institute for Health and Care Excellence

Conteúdo relacionado: #ESCCongress – 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – SGLT2 inhibitors are now recommended for patients with heart failure with reduced ejection fraction regardless of the presence of diabetes.

Retrospectiva: principais artigos de 2021 sobre doenças infecciosas além da COVID.

17 Dez, 2021 | 12:06h

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021 – IDStewardship

 

Comentário no Twitter

 

Medicamento da Merck contra COVID perde seu brilho: o que isso significa para a pandemia – “Molnupiravir foi inicialmente anunciado pelos oficiais de saúde pública como um elemento que mudaria o cenário da COVID-19, mas dados finais dos estudos clínicos mostraram eficácia abaixo das expectativas.”

16 Dez, 2021 | 13:04h

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Conteúdos relacionados:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Encefalite autoimune após infecção por SARS-CoV-2: frequência de casos, achados e desfechos.

16 Dez, 2021 | 13:01h

Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes – Neurology

 

Comentário no Twitter

 

[Comunicado de imprensa – ainda não publicado] Em análise final, pílula da Pfizer contra Covid mantém a eficácia de 89% em reduzir o risco de internação ou morte.

15 Dez, 2021 | 12:47h

Comunicado de imprensa: Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel Covid-19 oral antiviral treatment candidate in reducing risk of hospitalization or death

Comentários:

Pfizer’s Covid pill remains 89% effective in final analysis, company says – STAT

Pfizer confirms COVID pill’s results, potency versus omicron – Associated Press

Conteúdos relacionados:

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

 

Comentário no Twitter (fio – clique para saber mais)

 

Posicionamento científico | Diagnóstico, tratamento e prevenção da ingestão de baterias na infância.

15 Dez, 2021 | 12:33h

Diagnosis, Management, and Prevention of Button Battery Ingestion in Childhood: A European Society for Paediatric Gastroenterology Hepatology and Nutrition Position Paper – Journal of Pediatric Gastroenterology and Nutrition

Resumo visual: Diagnosis, Management, and Prevention of Button Battery Ingestion in Childhood

 

Comentário no Twitter (fio – clique para saber mais)

 

Revisão | Diagnóstico e tratamento da apendicite aguda em adultos.

15 Dez, 2021 | 12:30h

Diagnosis and Management of Acute Appendicitis in Adults: A Review – JAMA (gratuito por tempo limitado)

Entrevista com o autor: Current Management of Acute Appendicitis: Antibiotics or Surgical Intervention

Comentário: Antibiotics can be first-line therapy for uncomplicated appendicitis cases – Duke University Medical Center

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.